Lv2
170 积分 2022-08-01 加入
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
6天前
已完结
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
7天前
已完结
Peripheral cancer attenuates amyloid pathology in Alzheimer’s disease via cystatin-c activation of TREM2
1个月前
已完结
《中国多发性骨髓瘤诊治指南（2024年修订）》微小残留病疗效标准部分解读
2个月前
已完结
《中国多发性骨髓瘤诊治指南（2024年修订）》微小残留病疗效标准部分解读
3个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
3个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
3个月前
已完结
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
3个月前
已完结
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
3个月前
已完结
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression
4个月前
已完结
皖公网安备34019202002308
